Department of Pediatrics, Section of Pediatric Cardiology, Medical College of Wisconsin, Milwaukee, WI, USA; The Herma Heart Institute, Children's Wisconsin, Milwaukee, WI, USA.
Department of Pediatrics, Section of Pediatric Cardiology, Medical College of Wisconsin, Milwaukee, WI, USA; The Herma Heart Institute, Children's Wisconsin, Milwaukee, WI, USA.
J Mol Cell Cardiol. 2023 Oct;183:1-13. doi: 10.1016/j.yjmcc.2023.08.001. Epub 2023 Aug 12.
Cardiovascular calcification can occur in vascular and valvular structures and is commonly associated with calcium deposition and tissue mineralization leading to stiffness and dysfunction. Patients with chronic kidney disease and associated hyperphosphatemia have an elevated risk for coronary artery calcification (CAC) and calcific aortic valve disease (CAVD). However, there is mounting evidence to suggest that the susceptibility and pathobiology of calcification in these two cardiovascular structures may be different, yet clinically they are similarly treated. To better understand diversity in molecular and cellular processes that underlie hyperphosphatemia-induced calcification in vascular and valvular structures, we exposed aortic vascular smooth muscle cells (AVSMCs) and aortic valve interstitial cells (AVICs) to high (2.5 mM) phosphate (Ph) conditions in vitro, and examined cell-specific responses. To further identify hyperphosphatemic-specific responses, parallel studies were performed using osteogenic media (OM) as an alternative calcific stimulus. Consistent with clinical observations made by others, we show that AVSMCs are more susceptible to calcification than AVICs. In addition, bulk RNA-sequencing reveals that AVSMCs and AVICs activate robust ossification-programs in response to high phosphate or OM treatments, however, the signaling pathways, cellular processes and osteogenic-associated markers involved are cell- and treatment-specific. For example, compared to VSMCs, VIC-mediated calcification involves biological processes related to osteo-chondro differentiation and down regulation of 'actin cytoskeleton'-related genes, that are not observed in VSMCs. Furthermore, hyperphosphatemic-induced calcification in AVICs and AVSMCs is independent of P13K signaling, which plays a role in OM-treated cells. Together, this study provides a wealth of information suggesting that the pathogenesis of cardiovascular calcifications is significantly more diverse than previously appreciated.
心血管钙化可发生于血管和瓣膜结构中,通常与钙沉积和组织矿化有关,导致僵硬和功能障碍。患有慢性肾脏病和相关高磷血症的患者,其冠状动脉钙化(CAC)和钙化性主动脉瓣疾病(CAVD)的风险增加。然而,越来越多的证据表明,这两种心血管结构中钙化的易感性和病理生物学可能不同,但临床上它们的治疗方式相似。为了更好地理解高磷血症诱导的血管和瓣膜结构钙化的分子和细胞过程的多样性,我们在体外将主动脉血管平滑肌细胞(AVSMCs)和主动脉瓣间质细胞(AVICs)暴露于高(2.5 mM)磷(Ph)条件下,并检查了细胞特异性反应。为了进一步确定高磷血症特异性反应,我们还使用成骨培养基(OM)作为替代钙化刺激物进行了平行研究。与其他人的临床观察一致,我们发现 AVSMCs 比 AVICs 更容易发生钙化。此外,批量 RNA 测序表明,AVSMCs 和 AVICs 对高磷酸盐或 OM 处理均会激活强有力的成骨程序,但是涉及的信号通路、细胞过程和与成骨相关的标记物是细胞和处理特异性的。例如,与 VSMCs 相比,VIC 介导的钙化涉及与骨软骨分化相关的生物学过程,以及与“肌动蛋白细胞骨架”相关基因的下调,而这些在 VSMCs 中未观察到。此外,AVICs 和 AVSMCs 中的高磷血症诱导的钙化独立于 P13K 信号通路,而该信号通路在 OM 处理的细胞中发挥作用。总之,这项研究提供了丰富的信息,表明心血管钙化的发病机制比以前认为的要多样化得多。